Skip to main content

rocakinogene sifuplasmid

Generic: Rocakinogene Sifuplasmid

rocakinogene sifuplasmid: 4 clinical trials tracked.

rocakinogene sifuplasmid evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about rocakinogene sifuplasmid, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trials (4)

Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations

NCT04367675·Phase 1
Active, not recruiting

Primary endpoint: Dose Limiting Toxicities

Interventionalopen44 targetStarted 2021-04Completion 2027-031 site · United StatesAbramson Cancer Center at Penn Medicine

An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)

NCT03491683·Phase 1/Phase 2·INO

Primary endpoint: Percentage of Participants with Adverse Events (AEs)

Interventionalopen52 targetStarted 2018-05Completion 2026-1221 sites · United StatesInovio Pharmaceuticals

An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

NCT03502785·Phase 1/Phase 2·INO
Completed

Primary endpoint: Number of Adverse Events

Interventionalopen35 enrolledStarted 2018-05Completion 2025-0511 sites · United StatesInovio Pharmaceuticals

Phase I Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection

NCT02772003·Phase 1
Active, not recruiting

Primary endpoint: Incidence of dose-limiting toxicity

Interventionalsingle33 enrolledStarted 2016-06Completion 2027-035 sites · Puerto Rico, United StatesNational Cancer Institute (NCI)